EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail

Andrew Davis, Kamaljit Bajwa, Zachary Martinez, Ryan R Davis iD, April Green, Fletcher Suber, Shauna Farr-Jones iD, Milan T Tomic

Toxins · 23.04.2026 · 18 (5) · 199

DOI: 10.3390/toxins18050199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, online erschienen am 23.04.2026. Verfasst von Andrew Davis und 7 weiteren Autor:innen. Beteiligte Einrichtung: Resilience Government Services, 2061 Challenger Drive, Alameda, CA 94501, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Botulinum Antitoxin, Botulinum Toxins, Botulinum Toxins, Type A. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, Defense Threat Reduction Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A highly potent antitoxin for botulinum neurotoxin (BoNT) serotypes A and B has been developed that comprises three monoclonal antibodies (mAbs) targeting BoNT/A and three targeting BoNT/B. These oligoclonal antibody combinations neutralize toxin by simultaneously binding non-overlapping epitopes, thereby promoting rapid toxin clearance. All six mAbs use the same human Fc and framework and have been individually manufactured using the same expression platform and purification process. To minimize the time and labor required to produce the divalent antitoxin, we tested a co-expression and co-purification strategy for the three mAbs per serotype. The mAbs were expressed in CHO-K1 cells, and the media were optimized for co-expression in 10 L bioreactors. Chromatographic co-purification consisted of Protein A capture, followed by strong anion exchange chromatography in flow-through mode and cation-exchange chromatography in bind-elute mode. Co-expression experiments demonstrated that expression of the three anti-BoNT/A antibodies remained within approximately ±30% of the optimal equimolar ratio, whereas the anti-BoNT/B antibodies showed greater variability. Downstream purification steps achieved recoveries greater than 95% per chromatographic step, resulting in overall process yields of approximately 63–75%. This strategy provided sufficient purity of all six mAbs while largely preserving their relative ratios. These results demonstrate the feasibility of producing oligoclonal antitoxin antibodies using co-expression and shared purification strategies. Such approaches may simplify the manufacturing of antibody cocktails while maintaining product quality and biological activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalBotulinum AntitoxinBotulinum ToxinsBotulinum Toxins, Type AAnimalsCHO CellsCricetulusHumansCombined Antibody Therapeutics

Stichwörter der Autor:innen

botulinum antitoxinco-expressionco-purificationoligoclonal antibodiesrecombinant antibody manufacturing

Substanzen

Antibodies, MonoclonalBotulinum AntitoxinBotulinum ToxinsBotulinum Toxins, Type ACombined Antibody Therapeutics

Autor:innen und Institutionen

  • Resilience Government Services, 2061 Challenger Drive, Alameda, CA 94501, USA.
  • Resilience Government Services, 13200 NW Nano Court, Alachua, FL 32615, USA.
  • Department of Anesthesia, University of California, 1001 Potrero Ave, San Francisco, CA 94110, USA.

ORCID-Profile: Ryan R Davis, Shauna Farr-Jones

Förderung

  • United States Department of Defense
  • Defense Threat Reduction Agency

Zitieren

APA

Davis, A., Bajwa, K., Martinez, Z., Davis, R. R., Green, A., Suber, F., Farr-Jones, S., & Tomic, M. T. (2026). Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail. Toxins, 18(5), 199. https://doi.org/10.3390/toxins18050199

Vancouver

Davis A, Bajwa K, Martinez Z, Davis RR, Green A, Suber F, et al. Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail. Toxins. 2026;18(5):199. doi:10.3390/toxins18050199

BibTeX
@article{Davis2026,
  author = {Davis, Andrew and Bajwa, Kamaljit and Martinez, Zachary and Davis, Ryan R and Green, April and Suber, Fletcher and Farr-Jones, Shauna and Tomic, Milan T},
  title = {Co-Expression and Co-Purification Enable Manufacturing of a Six-Monoclonal Antibody Botulinum Antitoxin Cocktail},
  journal = {Toxins},
  year = {2026},
  volume = {18},
  number = {5},
  pages = {199},
  doi = {10.3390/toxins18050199}
}
Kostenlos starten →